白蛋白给药对低白蛋白血症社区获得性肺炎住院患者结局的影响(ALBUCAP):一项前瞻性、随机、III期临床对照试验的试验方案
本研究为一项多中心、非盲、随机、III期优效性对照试验方案,旨在评估在低白蛋白血症(≤30 g/L)的社区获得性肺炎(CAP)住院患者中,与单纯标准治疗相比,加用白蛋白(20 g/100 mL,每12小时一次,共4天)能否提高第5天临床稳定患者的比例。主要终点为第5天临床稳定(生命体征稳定至少24小时)的患者比例(意向性治疗分析),计划样本量360例,来自西班牙三家医院。
要点
- 评估白蛋白对低白蛋白血症CAP住院患者第5天临床稳定比例的影响。
- 纳入标准:住院、低白蛋白血症(≤30 g/L)、非免疫抑制的成人CAP患者。
- 干预方案:标准治疗加白蛋白20 g/100 mL每12小时一次共4天,对照为单纯标准治疗。
核心结论
- 方案假设在低白蛋白血症CAP住院患者中,加用白蛋白较单纯标准治疗可提高第5天临床稳定患者比例。
- 若试验证实该假设,可能改变当前低白蛋白血症CAP患者的临床实践。
研究设计与样本
- 多中心、非盲、随机、III期、优效性、干预性对照临床试验方案。
- 计划从西班牙三家医院招募360例患者,招募期2年,按1:1随机分配。
- 样本量基于意向性治疗分析,双侧5% alpha水平,把握度80%。
主要发现
- 主要终点为第5天临床稳定患者比例(意向性治疗分析),临床稳定定义为生命体征稳定至少24小时。
- 次要终点包括临床稳定时间、静脉及总抗生素治疗时长、住院时长、ICU入住、机械通气及血管加压药治疗时长、不良事件、30天内再入院及全因死亡率。
关键数值与推荐
- 纳入标准:住院、低白蛋白血症(≤30 g/L)、非免疫抑制、成人、诊断为CAP。
- 干预组:标准治疗加白蛋白20 g(100 mL)每12小时一次,共4天;对照组:单纯标准治疗。
- 随访:出院后1个月进行随访访视。
临床怎么用
- 该方案尚处于试验阶段,结果未出,暂不能据此改变临床实践。
- 试验完成后若证实优效,可考虑对低白蛋白血症CAP住院患者加用白蛋白。
局限性
- 本文件为试验方案,尚无结果数据。
- 试验为非盲设计。
- 招募仅限西班牙三家医院,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone. METHODS: This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1 month after discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of 80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic (≤ 30 g/L), non-immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care plus albumin (20 g in 100 mL) every 12 h for 4 days or standard care alone. DISCUSSION: If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for the management of hypoalbuminemic patients with CAP. TRIAL REGISTRATION: European Clinical Trials Database (EudraCT) 2018-003117-18 . Registered on 12 April 2019. ClinicalTrials.gov NCT04071041 . Registered on 27 August 2019.
引用
- Rombauts A, Abelenda-Alonso G, Simonetti AF, et al. Effect of albumin administration on outcomes in hypoalbuminemic patients hospitalized with community-acquired pneumonia (ALBUCAP): a prospective, randomized, phase III clinical controlled trial-a trial protocol. Trials. 2020. PMID: 32819439. doi:10.1186/s13063-020-04627-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。